Mersana Capital Expenditures vs Cash Flows Other Operating Analysis
MRSN Stock | USD 2.30 0.02 0.88% |
Mersana Therapeutics financial indicator trend analysis is infinitely more than just investigating Mersana Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mersana Therapeutics is a good investment. Please check the relationship between Mersana Therapeutics Capital Expenditures and its Cash Flows Other Operating accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
Capital Expenditures vs Cash Flows Other Operating
Capital Expenditures vs Cash Flows Other Operating Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mersana Therapeutics Capital Expenditures account and Cash Flows Other Operating. At this time, the significance of the direction appears to have no relationship.
The correlation between Mersana Therapeutics' Capital Expenditures and Cash Flows Other Operating is 0.08. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Cash Flows Other Operating in the same time period over historical financial statements of Mersana Therapeutics, assuming nothing else is changed. The correlation between historical values of Mersana Therapeutics' Capital Expenditures and Cash Flows Other Operating is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Mersana Therapeutics are associated (or correlated) with its Cash Flows Other Operating. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash Flows Other Operating has no effect on the direction of Capital Expenditures i.e., Mersana Therapeutics' Capital Expenditures and Cash Flows Other Operating go up and down completely randomly.
Correlation Coefficient | 0.08 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Capital Expenditures
Capital Expenditures are funds used by Mersana Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Mersana Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Cash Flows Other Operating
Most indicators from Mersana Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mersana Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.As of the 3rd of December 2024, Selling General Administrative is likely to grow to about 62.5 M, while Issuance Of Capital Stock is likely to drop about 118.6 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 855K | 927K | 1.5M | 1.1M | Interest Income | 65K | 2.9M | 11.0M | 11.6M |
Mersana Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Mersana Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Mersana Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 107.5M | 273.4M | 206.1M | 334.3M | 226.1M | 180.4M | |
Other Current Liab | 9.1M | 16.2M | 29.0M | 44.2M | 22.7M | 17.9M | |
Total Current Liabilities | 24.1M | 30.0M | 47.5M | 91.5M | 63.6M | 48.5M | |
Total Stockholder Equity | 78.3M | 228.1M | 121.7M | 92.1M | 36.9M | 65.7M | |
Other Liab | 28.8M | 282K | 525K | 117.0M | 134.6M | 141.3M | |
Net Tangible Assets | 78.3M | 228.1M | 155.5M | 92.1M | 105.9M | 73.5M | |
Property Plant And Equipment Net | 4.8M | 12.7M | 14.9M | 14.5M | 11.5M | 8.2M | |
Current Deferred Revenue | 4.8M | 4.0M | 3.9M | 30.6M | 28.1M | 20.7M | |
Net Debt | (54.6M) | (238.5M) | (139.8M) | (244.4M) | (140.7M) | (147.8M) | |
Retained Earnings | (192.4M) | (280.4M) | (450.5M) | (654.7M) | (826.4M) | (785.0M) | |
Accounts Payable | 7.3M | 8.3M | 12.3M | 14.0M | 7.3M | 8.2M | |
Cash | 62.4M | 255.1M | 177.9M | 280.7M | 174.6M | 140.4M | |
Non Current Assets Total | 6.2M | 14.8M | 17.2M | 15.1M | 12.0M | 11.2M | |
Non Currrent Assets Other | 1.1M | 2.2M | 1.9M | 183K | 478K | 454.1K | |
Other Assets | 1.5M | 13.1M | 2.4M | 661K | 760.2K | 722.1K | |
Cash And Short Term Investments | 99.8M | 255.1M | 177.9M | 280.7M | 209.1M | 161.3M | |
Common Stock Shares Outstanding | 43.5M | 61.5M | 70.6M | 93.7M | 116.1M | 121.9M | |
Liabilities And Stockholders Equity | 107.5M | 273.4M | 206.1M | 334.3M | 226.1M | 180.4M | |
Non Current Liabilities Total | 5.2M | 15.3M | 36.8M | 150.8M | 125.5M | 66.2M | |
Capital Surpluse | 173.0M | 270.7M | 508.5M | 572.2M | 658.0M | 690.9M | |
Other Current Assets | 1.5M | 3.5M | 21.9M | 8.5M | 5.0M | 5.8M | |
Other Stockholder Equity | 270.7M | 508.5M | 572.2M | 746.9M | 863.2M | 906.4M | |
Total Liab | 29.2M | 45.3M | 84.4M | 242.3M | 189.2M | 114.7M | |
Property Plant And Equipment Gross | 4.8M | 12.7M | 22.5M | 22.2M | 20.6M | 11.2M | |
Total Current Assets | 101.3M | 258.6M | 188.9M | 319.2M | 214.1M | 169.2M | |
Accumulated Other Comprehensive Income | (8K) | 25K | 0.0 | (152K) | 11K | 11.6K | |
Property Plant Equipment | 4.8M | 1.7M | 14.9M | 14.5M | 16.6M | 17.5M | |
Retained Earnings Total Equity | (164.2M) | (192.4M) | (280.4M) | (450.5M) | (405.4M) | (385.2M) | |
Short Term Investments | 10.5M | 37.4M | 0.0 | 151.8M | 34.5M | 50.7M | |
Net Invested Capital | 83.2M | 233.1M | 146.4M | 117.0M | 62.1M | 113.2M | |
Net Working Capital | 77.3M | 228.6M | 141.4M | 227.7M | 150.4M | 143.9M |
Pair Trading with Mersana Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mersana Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mersana Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Mersana Stock
0.72 | VALN | Valneva SE ADR | PairCorr |
0.5 | DRRX | Durect | PairCorr |
0.45 | ME | 23Andme Holding | PairCorr |
0.43 | VCNX | Vaccinex | PairCorr |
0.33 | EQ | Equillium | PairCorr |
The ability to find closely correlated positions to Mersana Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mersana Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mersana Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mersana Therapeutics to buy it.
The correlation of Mersana Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mersana Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mersana Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mersana Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.